Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Switching from efavirenz to etravirine for persistent CNS toxicity in HIV
2008-000674-20Phase 3Completed
- Sponsor
- St Stephen's AIDS Trust
- Start
- Feb 2008
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in human immunodeficiency virus infection (HIV) comparing Switch to etravirine (TMC125) with Continue efavirenz (placebo-controlled) (2 arms). Primary endpoint: Neuropsychiatric and CNS toxicity rate at 12 weeks. Started Feb 2008; status: completed.
02
Drugs
efavirenzetravirine
03
Conditions
human immunodeficiency virus infection (HIV)
Beyond the preview
Go deeper on 2008-000674-20.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2008-000674-20.